Last reviewed · How we verify

Tecentriq (atezolizumab)

Roche · FDA-approved active Monoclonal antibody Verified Quality 79/100

Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system.

Tecentriq (atezolizumab) is a programmed death receptor-1 blocking antibody developed by Genentech Inc. It targets the programmed cell death 1 ligand 1, a protein that can help cancer cells evade the immune system. Tecentriq is approved to treat various types of cancer, including lung, breast, liver, and bladder cancers. The drug has a half-life of 27 days and is still patented. Key safety considerations include immune-mediated reactions and infusion-related reactions.

At a glance

Generic nameatezolizumab
SponsorRoche
Drug classProgrammed Death Receptor-1 Blocking Antibody [EPC]
TargetProgrammed cell death 1 ligand 1
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approval2016
Annual revenue3700

Mechanism of action

PD-L1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.Atezolizumab is monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors. This releases the PD-L1/PD-1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in decreased tumor growth.In mouse models of cancer, dual inhibition of the PD-1/PD-L1 and MAPK pathways suppresses tumor growth and improves tumor immunogenicity through increased antigen presentation and cell infiltration and activation compared t

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: